RBC Capital analyst Leonid Timashev initiates coverage on $Applied Therapeutics (APLT.US)$ with a hold rating, and sets the target price at $12.
According to TipRanks data, the analyst has a success rate of 50.6% and a total average return of 17.9% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Applied Therapeutics (APLT.US)$'s main analysts recently are as follows:
The Complete Response Letter issued by the FDA for govorestat in galactosemia was unexpected and confusing, especially as the FDA seemed unable to overlook the missed primary endpoint when considering full approval. The likelihood of success in galactosemia is now perceived at 50%, following this recent regulatory feedback. Nonetheless, the SORD program, which is assessed separately under accelerated approval by Neurology I, is considered to represent significant value, justifying continued positive sentiment towards the company's prospects.
The FDA's issuance of a complete response letter for govorestat in the treatment of galactosemia was seen as a significant setback, perceived to harm the drug's credibility in a manner difficult to recover from. Details regarding the adverse aspects of the review remain scarce. Expectations have shifted, indicating that forthcoming reviews in similar treatments are likely to be met with increased skepticism by the investment community. Nonetheless, the potential for a commercial opportunity remains robust, with anticipations of a recovery in valuation following potential approval in the coming year.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
加皇資本市場分析師Leonid Timashev首次給予$Applied Therapeutics (APLT.US)$持有評級，目標價12美元。
根據TipRanks數據顯示，該分析師近一年總勝率為50.6%，總平均回報率為17.9%。
此外，綜合報道，$Applied Therapeutics (APLT.US)$近期主要分析師觀點如下：
美國食品和藥物管理局針對半乳糖血症的govorestat發佈的完整回覆信出乎意料且令人困惑，尤其是因爲美國食品和藥物管理局在考慮全面批准時似乎無法忽視錯過的主要終點。根據最近的監管反饋，目前人們認爲半乳糖血症成功的可能性爲50％。儘管如此，在Neurology I的加速批准下單獨評估的SORD計劃被認爲具有重大價值，這證明了對公司前景的持續樂觀情緒。
美國食品藥品管理局發佈了關於govorestat治療半乳糖血症的完整回覆信，這被視爲重大挫折，被認爲損害了該藥物的可信度，難以恢復。有關審查不利方面的細節仍然很少。預期發生了變化，這表明即將進行的類似療法審查可能會受到投資界越來越多的懷疑。儘管如此，商業機會的潛力仍然強勁，預計在來年可能獲得批准後，估值將回升。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
